Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Ophthalmic Drug Delivery Systems

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...

Oral Drug Delivery Systems: Continuous-Release Systems

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...

Oral Drug Delivery Systems: Delayed-Release Systems

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...

Modified-Release Drug Delivery Systems: Rate-Programmed II

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...

Modified-Release Drug Delivery Systems: Stimuli-Activated

Modified-Release Drug Delivery Systems: Stimuli-Activated

Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Exploring the Role of the Zeis Gland in Dry Eye Disease Associated with Demodex Blepharitis.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics·2026

Same author

Tear Film Imager Findings Support a New Perspective on the Mechanisms of Tear Film Thinning in Healthy Subjects.

Investigative ophthalmology & visual science·2026

Same author

<i>"Solid Hollows"</i> and "<i>Reverspectives"</i>: Similarities and differences.

i-Perception·2026

Same author

A Learner-Driven Workshop to Enhance Feedback Engagement in Emergency Medicine.

Cureus·2026

Same author

Rare Lupus Exacerbation Shines Light on Provider Bias in a Patient With Possible Autoimmune Hepatitis.

Cureus·2025

Same author

Corneal Endothelial Cell Loss From Anterior Chamber Paracentesis in a Porcine Model.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics·2025

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

Biodegradable implants for sustained drug release in the eye.

Susan S Lee¹, Patrick Hughes, Aron D Ross

¹Allergan, Inc., 2525 Dupont Dr., Irvine, CA 92612, USA. lee_susan@allergan.com

Pharmaceutical Research

|June 11, 2010

Summary

Biodegradable polymers offer improved ocular drug delivery, overcoming limitations of traditional therapies. These advanced systems enhance drug uptake and patient adherence for treating eye diseases.

More Related Videos

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

Related Experiment Videos

Last Updated: Jun 12, 2026

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

Area of Science:

Ophthalmology
Biomaterials Science
Drug Delivery Systems

Background:

Current ocular therapies face challenges like poor drug penetration, systemic side effects, and low patient adherence.
Intravitreal injections improve ocular drug delivery but require frequent administration and carry risks.
Sustained-release systems offer a solution by prolonging therapeutic drug levels and reducing systemic exposure.

Purpose of the Study:

To review the development and application of biodegradable drug delivery systems for ocular disorders.
To highlight the role of biocompatible polymers in enhancing ocular drug delivery.
To discuss the safety and efficacy of biodegradable ocular implants.

Main Methods:

Review of literature on biocompatible polymers for ocular drug delivery.
Analysis of synthetic aliphatic polyesters (polylactic acid, polyglycolic acid, PLGA) in biodegradable implants.
Examination of pharmacological properties, safety, and clinical effectiveness data.

Main Results:

Biodegradable polymers enable tailored drug release kinetics for specific ocular conditions.
Synthetic polyesters are key materials for safe and effective biodegradable ocular implants.
These systems demonstrate potential for improved therapeutic outcomes and patient compliance.

Conclusions:

Biodegradable drug implants represent a significant advancement in ocular drug delivery.
Polymer-based sustained-release systems can overcome major limitations of conventional ocular treatments.
Further research into these systems promises enhanced treatment of various eye diseases.